These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9256829)

  • 21. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study.
    Mantadakis E; Herrera L; Leavey PJ; Bash RO; Winick NJ; Kamen BA
    J Clin Oncol; 2000 Jul; 18(13):2576-81. PubMed ID: 10893289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.
    Toner GC; Green M; Bishop JF; McKendrick J; Cebon J; Sheridan WP; Lockbaum P; O'Byrne J; Fox RM
    Am J Clin Oncol; 1998 Jun; 21(3):263-9. PubMed ID: 9626795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
    Tornesello A; Mastrangelo S; Piciacchia D; Bembo V; Colosimo C; Di Rocco C; Mastrangelo R
    J Neurooncol; 1999; 45(2):135-40. PubMed ID: 10778729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor.
    Dagher R; Kreissman S; Robertson KA; Provisor A; Bergstein J; Burke K; Rodman JH; Emanuel D; Smith FO
    J Pediatr Hematol Oncol; 1998; 20(4):357-60. PubMed ID: 9703013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
    Patnaik A; MacKinnon J; Goss P; Nagy T; Stewart K; Keating A; Crump M
    J Clin Oncol; 2000 Jun; 18(12):2363-8. PubMed ID: 10856095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
    Fernandez MC; Krailo MD; Gerbing RR; Matthay KK
    Cancer; 2000 Jun; 88(12):2838-44. PubMed ID: 10870069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Loss JF; Santos PP; Leone LD; Brunetto AL
    Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose cyclophosphamide, adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor.
    Zoubek A; Holzinger B; Mann G; Peters C; Emminger W; Perneczky-Hintringer E; Gadner H; Mostbeck G; Horcher E; Dobrowsky W
    Pediatr Hematol Oncol; 1994; 11(6):613-23. PubMed ID: 7857784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
    Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
    J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
    Rusthoven J; Levin L; Eisenhauer E; Mazurka J; Carmichael J; O'Connell G; Bryson P; Hirte H; Koski B
    J Natl Cancer Inst; 1991 Dec; 83(23):1748-53. PubMed ID: 1770554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
    Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS;
    Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.